Switzerland's Alcon Q3 sales slightly miss estimates despite surgical equipment launches, vision care growth
Switzerland's Alcon Q3 sales slightly miss estimates despite surgical equipment launches, vision care growth
Overview
Switzerland's eye care company Q3 sales rose 5% yr/yr, a slight miss versus analyst expectations
Core diluted EPS for Q3 beat analyst expectations
Growth driven by innovation and new products, offset by U.S. implantables competition
Outlook
Alcon expects 2026 net sales growth of about 6% in constant currency
Company forecasts 2026 core operating margin to rise 100-150 basis points vs prior year
Alcon projects 2026 core diluted EPS growth of 12% to 14% in constant currency
Result Drivers
CONSUMABLES AND PROCEDURAL VOLUMES - Co said higher surgical consumables sales were driven by increased procedural volumes and price increases
PREMIUM PRODUCTS AND PRICE INCREASES - Co said Vision Care growth was led by premium contact lenses and price increases, especially in the U.S.
INTERNATIONAL MARKETS AND NEW PRODUCTS - Co said international markets and new products like PanOptix Pro helped offset U.S. implantables decline
Company press release: ID:nBw8xVDnPa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Sales | Slight Miss* | $2.72 bln | $2.74 bln (14 Analysts) |
Q3 Core Diluted EPS | Beat | $0.91 | $0.87 (13 Analysts) |
Q3 EPS |
| $0.54 |
|
Q3 Core Operating Margin |
| 21.80% |
|
Q3 Operating Margin |
| 14.00% |
|
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 3 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Alcon AG is CHF77.35, about 25% above its November 10 closing price of CHF61.88
The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 19 three months ago
Reuters Recommended Reads
Nov 10 - Legend Biotech Q3 revenue rises slightly less than expected
Nov 9 - Annexon Biosciences Q3 net loss narrows on lower R&D expenses, cash runway extends to 2028
Nov 10 - Watches of Switzerland lifts outlook floor as US, UK demand remains strong
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Alcon AG
See all newsSwiss stocks - Factors to watch on November 12
Alcon AG reports results for the quarter ended September 30 - Earnings Summary
Alcon shares fall as tighter eye-care market outlook raises growth concerns (updated)
Alcon seen down after sales miss, tighter outlook
Swiss stocks - Factors to watch on November 11